Generic Drugs Stocks Review (Ligand Pharmaceuticals Inc, Hi-Tech Pharmacal Co, Actavis Inc, Momenta Pharmaceuticals)

Las Vegas, NV -- (SBWIRE) -- 02/27/2013 -- Cogonews.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) shares decreased 0.10% and closed at $20.50. Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs.

Can LGND Recover After The Recent fall? Find Out Here

Hi-Tech Pharmacal Co. (NASDAQ:HITK) shares fell 0.80% to $35.86. Hi-Tech Pharmacal Co., Inc. (Hi-Tech), is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. Hi-Tech develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands.

Can HITK Recover Now? Find Out Here

Actavis Inc (NYSE:ACT) shares added 1.84% and closed at $84.67. Actavis Inc., formerly Watson Pharmaceuticals, Inc., is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products.

How Should Investors Trade ACT Now? Find Out Here

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) stock increased 1.99% to $12.80. Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs.

Get Free Trend Analysis on To Know More About MNTA Here

About Cogo News
Cogonews.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.

Disclaimer
The assembled information disseminated by cogonews.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. cogonews.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.

Contact:
cogonews.com
editor@cogonews.com